Dr. Merchant is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
8700 Beverly Blvd., A9102
Los Angeles, CA 90048Phone+1 310-423-1160- Is this information wrong?
Summary
- Dr. Akil Merchant is co-Director of the Lymphoma Program at Cedars-Sinai Medical Center in Los Angeles, CA. He did his fellowship in Medical Oncology at Johns Hopkins University and was on the faculty at LAC-USC and the USC Norris Cancer center. He specializes lymphoma treatment and cellular therapies including CART and bone marrow transplantation.
Clinical Expertise
- Bone marrow transplantation, Leukemia, Hematologic oncology, Myeloproliferative disease, Oropharyngeal lymphoma
Education & Training
Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2005 - 2008
Baylor College of MedicineResidency, Internal Medicine, 2000 - 2005- Baylor College of MedicineClass of 2000
Certifications & Licensure
CA State Medical License 2012 - 2025
MD State Medical License 2005 - 2013
TX State Medical License 2002 - 2005- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Safety and Efficacy Study of Pracinostat With Azacitadine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML) Start of enrollment: 2013 Dec 24
- Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA Start of enrollment: 2013 Dec 01
- EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia Start of enrollment: 2018 May 09
- Join now to see all
Publications & Presentations
PubMed
- Spatiotemporal architecture of immune cells and cancer-associated fibroblasts in high-grade serous ovarian carcinoma.Alexander M Xu, Marcela Haro, Ye Hu, Sandra Orsulic, Ann E Walts, Joshi John, Beth Y Karlan, Akil Merchant> ;Science Advances. 2024 Apr 19
- Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma.Tomohiro Aoki, Aixiang Jiang, Alexander Xu, Yifan Yin, Alicia Gamboa, Katy Milne, Katsuyoshi Takata, Tomoko Miyata-Takata, Shanee Chung, Shinya Rai, Shaocheng Wu, Mary...> ;Journal of Clinical Oncology. 2024 Mar 20
- 1 citationsInnate and adaptive immune cell interaction drives inflammasome activation and hepatocyte apoptosis in murine liver injury from immune checkpoint inhibitors.Alavifard, H., Mohamed, M., Baktash, A., Mahov, S., Murray, S., Liu, Z., Shojaie, L., Bogdanov, J., Ali, M., Kanel, G., Ito, F., In, G., Merchant, A., Stohl, W., Dara, L.> ;Cell Death & Disease. 2024 Feb 14
- Join now to see all
Abstracts/Posters
- Single Cell Transcriptome Analysis Reveals Disease-Defining T Cell Subsets in the Tumor Microenvironment of Classic Hodgkin LymphomaAkil Merchant, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Highly Multiplexed Single Cell Spatial Analysis of the Tumor Microenvironment in Lymphoma Predicts Clinical OutcomesAkil Merchant, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
A Leading-Edge Lymphoma ProgramDecember 21st, 2022- The More Pandemic Precautions Fall Away, the More COVID Risk Is Concentrated on This One GroupDecember 2nd, 2022
- Cell Diversity Could Spell Trouble for Animal Models of CancerNovember 19th, 2021
- Join now to see all
Hospital Affiliations
Cedars-Sinai Medical CenterLos Angeles, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
